The Medicines Company
Also known as: Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) | THE MEDICINES CO | The Medicines Company | The Medicines Company - Medical Director, Clinical Operations | The Medicines Company (Schweiz) GmbH
Highest phase reached
Phase 4
First clinical trial
Apr 1, 1999First marketed drug
Dec 15, 2000First NDA
Dec 15, 2000Last known activity
Apr 16, 2019
Timeline
1990s
- Jan 1, 1996
The Medicines Company— Founded
2000s
- Dec 15, 2000
bivalirudin— NDA Organization
- May 22, 2006
fentanyl— NDA Secondary Org
- Jan 1, 2009
Targanta— Acquired
2010s
- Jan 1, 2012
Incline Therapeutics— Acquired
- Jan 1, 2013
Rempex Pharmaceuticals— Acquired
- Aug 6, 2013
ProFibrix— Acquired
- Jan 1, 2014
Tenaxis Medical— Acquired
- Feb 4, 2015
Annovation BioPharma— Acquired
- Nov 25, 2019
Novartis— Acquired By
Drugs by trial phase (33 distinct, 86 trials)
Phase 4 (2 own, 2 via acquisition)
Phase 3 (18 own, 0 via acquisition)
Phase 2 (5 own, 0 via acquisition)
Phase 1 (5 own, 1 via acquisition)
Indications
Studied for
- Abscess
- Acute Coronary Syndrome
- Acute Disease
- Acute Kidney Injury
- Aneurysm
- Angina, Unstable
- Aortic Aneurysm
- Aortic Diseases
- Aortic Valve Stenosis
- Atherosclerosis
- Bacteremia
- Bacterial Infections
- Brain Neoplasms
- Cardiovascular Diseases
- Cellulitis
- Cerebral Hemorrhage
- Communicable Diseases
- Coronary Artery Disease
- Coronary Disease
- Dyspnea
- Emergencies
- Epilepsy
- Gram-Positive Bacterial Infections
- Healthcare-Associated Pneumonia
- Heart Diseases
- Heart Failure
- Hemorrhage
- Hypercholesterolemia
- Hyperlipoproteinemia Type II
- Hypertension
- Infarction
- Infections
- Inflammation
- Intraabdominal Infections
- Intracranial Hemorrhages
- Myocardial Infarction
- Myocardial Ischemia
- Pneumonia
- Pneumonia, Bacterial
- Pneumonia, Ventilator-Associated
- Postoperative Pain
- Pyelonephritis
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Skin Diseases
- Skin Diseases, Bacterial
- Spinal Injuries
- Subarachnoid Hemorrhage
- Syndrome
- Thrombocytopenia
- Thrombosis
- Urinary Tract Infections
- Wound Infection
Marketed drugs (6)
Subsidiaries (6 direct, 6 total across the full acquisition tree)
Recent trials (50)
- NCT03814187Lead sponsorPhase 3Apr 16, 2019
- NCT03851705Lead sponsorPhase 2/Phase 3Feb 6, 2019
- NCT03705234CollaboratorPhase 3Oct 30, 2018
- NCT03291158Lead sponsorPhase 1Apr 30, 2018
- NCT03399370Lead sponsorPhase 3Dec 21, 2017
- NCT03397121Lead sponsorPhase 3Nov 28, 2017
- NCT03400800Lead sponsorPhase 3Nov 1, 2017
- NCT03021083CollaboratorPhase 4Jul 1, 2017
- NCT03159416Lead sponsorPhase 1Jun 1, 2017
- NCT02808052CollaboratorPhase 1May 1, 2017
- NCT02808052Lead sponsorPhase 1May 1, 2017
- NCT02802631CollaboratorPhase 1Apr 20, 2017
- NCT02802631Lead sponsorPhase 1Apr 20, 2017
- NCT03060577Lead sponsorPhase 2Mar 1, 2017
- NCT03060577Study directorPhase 2Mar 1, 2017
Details
- Founded
- Parsippany, NJ, US Jan 1, 1996
- First NDA
- Dec 15, 2000
- Last known activity
- Apr 16, 2019